Ollin Biosciences
PrivateLast Round
Series B
Jun 24, 2026
Est. Valuation
$500M
Total Funding Raised
$430M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
Ollin Biosciences is a biopharmaceutical company that develops therapies for vision-threatening ophthalmic diseases such as wet age-related macular degeneration and diabetic macular edema.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Clinical Trials, Drug Discovery
Business Model
B2B
Customer Profile
Revenue Share, Government Contracts
AI Layer
Application
Keywords
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Ollin Biosciences Comparables
Compare Ollin Biosciences with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Kodiak Sciences Inc. | 79% | |
| VelaVigo | 77% | |
| 4DMT | 77% |
Ollin Biosciences Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | Jun 24, 2026 | ||||
| Series A | Sep 17, 2025 |
Ollin Biosciences Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| Andreessen Horowitz | Series B |
| CPP Investments | Series B |
| RA Capital Management | Series B |
| TCG Crossover | Series B |
| ARCH Venture Partners | Series B, Series A |
| Commodore Capital | Series B |
| Monograph Capital | Series B, Series A |
Market signals
Structured signals derived from secondary market and firmographic data.
- Aug 29, 2026
Grew 35% QoQ from 20 to 27 employees.
- Jul 25, 2026
Grew 59% QoQ, from 17 to 27 employees.
Recent news
Latest coverage and updates
- attends_eventJul 13, 2026
Ollin Biosciences, Inc. attended event 44th annual scientific meeting on Jul 13th '26.
- attends_eventJul 13, 2026
Ollin Biosciences, Inc. attended event American Society of retina specialists on Jul 13th '26.
- hiresJun 24, 2026
Ollin Biosciences, Inc. hires Cariad Chester as board of directors.
- receives_financingJun 24, 2026
Ollin Biosciences, Inc. received financing of $100M in Series A on Jul 1st '25.
- receives_financingJun 24, 2026
Ollin Biosciences, Inc. received financing of $330M in Series B on Jun 24th '26.
Ollin Biosciences Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Request accessFrequently Asked Questions
Common questions about Ollin Biosciences's valuation, stock price, and market status.
Is Ollin Biosciences, Inc. a public or private company?
Ollin Biosciences, Inc. is a private company.
What is the current stock price of Ollin Biosciences, Inc.?
Ollin Biosciences, Inc. is a private company with no public stock price. No recent secondary market data is available.
How much is Ollin Biosciences, Inc. worth (valuation)?
Ollin Biosciences, Inc.'s valuation is estimated at $500.0M based on funding round data.
Can I buy Ollin Biosciences, Inc. stock?
Ollin Biosciences, Inc. shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors. Visit https://www.caplight.com to learn more.
When was Ollin Biosciences, Inc.'s last funding round?
Ollin Biosciences, Inc.'s most recent funding round was Series B on September 17, 2025.
Who are the main investors in Ollin Biosciences, Inc.?
Key investors in Ollin Biosciences, Inc. include TCG Crossover, ARCH Venture Partners, Monograph Capital, ARCH Venture Partners, TCG Crossover.
Will Ollin Biosciences, Inc. IPO soon?
No public IPO plans have been announced for Ollin Biosciences, Inc..
How can I track Ollin Biosciences, Inc. secondary market activity?
Caplight tracks bids, offers, and trades for private companies. Visit https://www.caplight.com to monitor Ollin Biosciences, Inc.'s secondary market activity and sign up for updates.